ArticleBMC veterinary research2026
Therapeutic efficacy monitoring in canine lymphoma patients via quantifying CDC6 plasma levels.
Article in BMC veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundLiquid biopsies have gained increasing recognition as minimally invasive ways to monitor treatment response in cancer patients. They carry circulating DNA, RNA, and proteins in and outside of extracellular vesicles (EVs). We have demonstrated that Cell Division Cycle 6 (CDC6), which is involved in controlling cell proliferation, was detected in circulating EVs and increased in the plasma of canine cancer patients compared to healthy control dogs. Here, we investigated whether plasma CDC6 mRNA levels can be used to monitor treatment response in dogs diagnosed with non-Hodgkin lymphoma, and we aimed to determine whether plasma expression is related to the systemic release of EVs.
methodsWe performed longitudinal proof-of-concept studies and collected platelet-free plasma (PFP) samples of 16 canine lymphoma patients before and during their chemo treatments at various time points, as well as PFP samples of 15 healthy control dogs. The EVs were isolated from PFP by size exclusion chromatography, further purified by density gradient ultracentrifugation, and quantified by high-resolution flow cytometry. The CDC6 mRNA abundance in both the unfractionated plasma and the EVs samples was measured by digital droplet PCR (ddPCR).
resultsThis study demonstrates that, in dogs with lymphoma, circulating CDC6 levels are increased compared to healthy controls. We show that CDC6 levels decline significantly in lymphoma patients that undergo remission in response to chemotherapy. Moreover we show that CDC6 mRNA levels correlate with the number of circulating EVs.
conclusionsOverall, our findings provides compelling evidence that plasma CDC6 mRNA expression can be used as a liquid biomarker to monitor treatment efficacy in dogs with lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.